Document is current
Any future updates will be listed below
-
Authors
Laletin, Vladimir
Bernard, Pierre-Louis
Costa da Silva, Cathy
Guittard, Geoffrey https://orcid.org/0000-0002-6061-8553
Nunes, Jacques A https://orcid.org/0000-0003-4865-0400
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04521413 at ClinicalTrials.govnct04649385 at ClinicalTrials.govDocuments that mention this clinical trial
489 TWT-101: a phase 1 study of the novel HPK1 inhibitor CFI-402411 in patients with advanced cancer
https://doi.org/10.1136/jitc-2021-sitc2021.489
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets
https://doi.org/10.1136/jitc-2022-005845
nct05128487 at ClinicalTrials.govDocuments that mention this clinical trial
A first-in-human phase 1a dose-escalation study of BGB-15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti-PD-1 antibody) in patients (pts) with advanced solid tumors.
https://doi.org/10.1200/jco.2024.42.16_suppl.2585
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets
https://doi.org/10.1136/jitc-2022-005845
nct05159700 at ClinicalTrials.govDocuments that mention this clinical trial
Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockade
https://doi.org/10.1136/jitc-2025-012064
Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: Clinical update.
https://doi.org/10.1200/jco.2024.42.16_suppl.3083
83 Tumor immune microenvironment characterization from pre- and post-dose tumors collected from a phase 1/2 study of NDI-101150, a hematopoietic progenitor kinase 1 (HPK1) inhibitor
https://doi.org/10.1136/jitc-2024-sitc2024.0083
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets
https://doi.org/10.1136/jitc-2022-005845
nct05233436 at ClinicalTrials.govDocuments that mention this clinical trial
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets
https://doi.org/10.1136/jitc-2022-005845
nct05370755 at ClinicalTrials.govDocuments that mention this clinical trial
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets
https://doi.org/10.1136/jitc-2022-005845
nct05107674 at ClinicalTrials.govDocuments that mention this clinical trial
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets
https://doi.org/10.1136/jitc-2022-005845
nct05107739 at ClinicalTrials.govDocuments that mention this clinical trial
Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation
https://doi.org/10.1136/jitc-2024-011180
Rescuing natural killer cells from the cancer wilderness
https://doi.org/10.1136/jitc-2025-011583
777 Initial clinical characterization of novel proximal biomarkers for NX-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced malignancies
https://doi.org/10.1136/jitc-2022-sitc2022.0777
824 NX-1607, a small molecule inhibitor of the CBL-B E3 ubiquitin ligase, promotes T and NK cell activation and enhances NK-mediated ADCC in a mouse lymphoma tumor model
https://doi.org/10.1136/jitc-2022-sitc2022.0824
810 NX-1607, a small molecule inhibitor of CBL-B, enhances anti-PD-1-mediated tumor growth inhibition by reshaping intratumoral innate and adaptive immune response
https://doi.org/10.1136/jitc-2023-sitc2023.0810
Targeting Cbl-b in cancer immunotherapy
https://doi.org/10.1136/jitc-2022-006007
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets
https://doi.org/10.1136/jitc-2022-005845
nct05662397 at ClinicalTrials.govDocuments that mention this clinical trial
254 The CBL-B inhibitor, NX-0255, enhances human drug enhanced tumor infiltrating lymphocyte (DeTIL) expansion and T cell function in full-scale runs
https://doi.org/10.1136/jitc-2022-sitc2022.0254
361 Universal expansion of CBL-B-inhibited tumor infiltrating lymphocytes, DeTIL-0255, from women with ovarian cancer: Process validation
https://doi.org/10.1136/jitc-2022-sitc2022.0361
Targeting Cbl-b in cancer immunotherapy
https://doi.org/10.1136/jitc-2022-006007
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets
https://doi.org/10.1136/jitc-2022-005845
671 A phase 1 adoptive cell therapy using drug-enhanced, tumor-infiltrating lymphocytes, DeTIL-0255, in adults with advanced malignancies
https://doi.org/10.1136/jitc-2022-sitc2022.0671
nct05315167 at ClinicalTrials.govDocuments that mention this clinical trial
1310 Peripheral blood and tumor gene expression as biomarkers and potential predictors of clinical outcome with HST-1011, an oral CBL-B inhibitor
https://doi.org/10.1136/jitc-2024-sitc2024.1310
55 Exploring proximal biomarkers of CBL-B inhibition in human peripheral blood mononuclear cells
https://doi.org/10.1136/jitc-2023-sitc2023.0055
Targeting Cbl-b in cancer immunotherapy
https://doi.org/10.1136/jitc-2022-006007
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets
https://doi.org/10.1136/jitc-2022-005845
nct04426669 at ClinicalTrials.govDocuments that mention this clinical trial
A phase I/II study to evaluate the safety, pharmacokinetics, and efficacy of PRJ1-3024 in patients with advanced solid tumors.
https://doi.org/10.1200/jco.2024.42.16_suppl.2590
1073 A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRJ1–3024in subjects with advanced solid tumors
https://doi.org/10.1136/jitc-2023-sitc2023.1073
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets
https://doi.org/10.1136/jitc-2022-005845
nct05566223 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma
https://doi.org/10.1136/jitc-2023-006822
Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity
https://doi.org/10.1136/jitc-2021-004244
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets
https://doi.org/10.1136/jitc-2022-005845
333 Targeting the apical intracellular checkpoint CISH unleashes T cell neoantigen reactivity and effector program
https://doi.org/10.1136/jitc-2020-sitc2020.0333
Documents that mention this clinical trial
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets
https://doi.org/10.1136/jitc-2022-005845
-
Funding
Funding for this research was provided by:
Institut National de la Santé et de la Recherche Médicale (N/A)
Institut Carnot OPALE (N/A)
Ligue Contre le Cancer (N/A)
Fondation d’Entreprise Bristol-Myers Squibb pour la Recherche en Immuno-Oncologie (N/A)
Centre National de la Recherche Scientifique (N/A)
Janssen Horizon Fonds de dotation (N/A)
Fondation ARC pour la recherche sur le Cancer (PJA20191209406)
Aix-Marseille Université (N/A)
- License Information
